DY
BCRX icon

Dowling & Yahnke’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dowling & Yahnke’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,000
Closed -$112K – 369
2021
Q1 		$112K Sell
11,000
-5,000
-31% -$51.6K 0.01% 333
2020
Q4 		$119K Hold
16,000
– – 0.01% 321
2020
Q3 		$55K Buy
16,000
+5,000
+45% +$21.4K ﹤0.01% 303
2020
Q2 		$52K Hold
11,000
– – ﹤0.01% 296
2020
Q1 		$22K Buy
+11,000
New +$30.3K ﹤0.01% 290

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dowling & Yahnke's BCRX Position: Q2 2021 in Review

Dowling & Yahnke sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 11,000 shares — an estimated $112K sold.

Dowling & Yahnke first reported a position in BCRX in Q1 2020 and held it in 5 quarters. The position peaked at $119K in Q4 2020. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Dowling & Yahnke reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Dowling & Yahnke sold 11,000 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $112K.
  • Dowling & Yahnke first reported a position in BioCryst Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Dowling & Yahnke's BioCryst Pharmaceuticals position peaked at $119K in Q4 2020.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Dowling & Yahnke's 13F filing for Q2 2021, filed 21 Jul 2021.